Definitive Guide to Nootropics

This content is for informational purposes only and is not a substitute for professional advice.

The safe way to think about nootropics is not "what makes me smarter?" It is "which input has enough human evidence, low enough risk, and a clean enough measurement window to deserve a trial?"

Unfair treats a nootropic as a cognitive hypothesis. The compound might affect alertness, fatigue resistance, memory encoding, recall, or sleep-mediated next-day performance. Each claim needs a domain, a time window, a risk screen, and a result you can track. Without those four pieces, a nootropic is just a story attached to a capsule.

What counts as a nootropic

The word nootropic is used broadly now. It can mean caffeine, L-theanine, creatine, bacopa, citicoline, lion's mane, nicotine, prescription wakefulness agents, and dozens of herbal products. That wide use is the problem. The category mixes food components, nutrients, botanicals, prescription drugs, gray-market compounds, and products with weak label transparency.

For consumer education, the safer definition is narrower. A nootropic is a substance used with the intent to support a measurable cognitive function in a defined context. It is not a treatment claim. It is not a promise of higher intelligence. It is not a substitute for sleep, clinical care, or a work system that makes attention possible.

FDA and NCCIH guidance matters here because dietary supplements are not approved by FDA for safety and effectiveness before sale, and products can carry risks, interaction concerns, and label problems.¹ FTC guidance matters because health-related claims need competent and reliable scientific evidence, usually human clinical testing, not mechanistic storytelling.²

The Unfair evidence tiers

Unfair ranks nootropic candidates by evidence quality first, then risk, then measurability. The point is not to crown winners. The point is to decide what deserves your next experiment.

This tiering can feel less exciting than a long shopping list. That is the point. Cognitive experiments are unusually vulnerable to placebo expectancy, sleep confounding, caffeine tolerance, and day-to-day workload changes. The first job is to reduce noise.

What the evidence supports best

The most defensible over-the-counter nootropic stack is still simple. Caffeine has the most reliable acute signal for alertness and sustained attention, with a known downside profile around anxiety, heart rate, tolerance, and sleep disruption. L-theanine can make caffeine feel smoother for some people, and a systematic review of tea constituents found moderate acute effects for caffeine plus L-theanine on alertness and attentional switching in the first two hours after dosing.³

Creatine is not an acute focus pill. It is an energy-buffering nutrient with stronger evidence in muscle performance than cognition. Cognitive findings are more context dependent, with signals often discussed around sleep deprivation, aging, vegetarian intake patterns, or metabolically demanding tasks.⁴ That makes creatine a better foundation candidate than a "take before writing" product.

Bacopa is one of the better-studied botanical nootropics, yet the honest claim is narrow. A review of randomized human trials found some evidence for memory free recall after 12-week trials using 300 to 450 mg daily extracts, with less evidence for other cognitive domains.⁵ That makes bacopa a memory experiment, not an all-purpose focus experiment.

Citicoline and other choline donors sit in a more conditional tier. Choline is a real nutrient needed for acetylcholine production, cell membranes, and other functions.⁶ A 12-week citicoline trial in healthy older adults with age-associated memory concerns reported improvement on episodic memory measures.⁷ That does not prove a healthy young adult with adequate choline intake should add choline.

The risk model comes before the stack

Nootropic risk is not only toxicity. It is also sleep loss, excess stimulation, medication interactions, product contamination, and poor attribution. A product can be pure, legal, and still be a bad fit for your situation.

If you are pregnant, breastfeeding, under 18, taking prescription medication, managing cardiovascular risk, preparing for surgery, or dealing with severe mood or sleep symptoms, treat nootropics as a clinician conversation rather than a self-experiment.

How to run a nootropic experiment

Most nootropic trials fail because the design is unreadable. The user adds caffeine, theanine, bacopa, a mushroom product, and a new sleep schedule at the same time, then declares the stack successful after a productive week. That is not evidence. That is a confounded week.

Good endpoints are boring and repeatable. Examples include words written in a 90-minute block, number of deep-work blocks completed, reaction-time task score, recall score on a fixed study deck, subjective focus on a 1 to 10 scale, sleep onset latency, and next-day energy. The endpoint does not need to be perfect. It needs to be measured the same way each day.

What to avoid

Avoid disease-treatment framing. A supplement page that says a nootropic treats ADHD, dementia, depression, traumatic brain injury, or insomnia is no longer making a simple structure-function claim. FDA explains that products intended to diagnose, treat, cure, or prevent disease are drugs, even if sold as supplements.¹

Avoid hidden-dose formulas. If a label does not disclose ingredient-level amounts, you cannot match the product to studies, screen overlap, or know whether the effect came from caffeine.

Avoid "more ingredients means more coverage." Cognition is not a slot machine. More inputs mean more interactions, more side effects, and less attribution.

Avoid late-day stimulant experiments. A nootropic that worsens sleep can look useful for a few days and then erase its own benefit through fatigue.

In Unfair

Unfair frames nootropics as ranked experiments. The app separates evidence tier, risk tier, dose window, interaction flags, and user response. A caffeine plus L-theanine test is tracked differently from bacopa because the onset, endpoint, and review date are different. A choline experiment is screened for overlap. A stimulant experiment is tied to sleep and resting heart-rate signals when those are available.

The right outcome is not a huge stack. The right outcome is a short list of inputs that earned their place through measured benefit, acceptable side effects, and a clear reason to stay.

References